©2024 Stanford Medicine
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Not Recruiting
Trial ID: NCT03733210
Purpose
This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying
cancer that has spread to the lymph nodes in patients with squamous cell head and neck
cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during
surgery to indicate cancerous tissue. 89Zr-panitumumab is a drug that contains a small amount
of radiation, which makes it visible in positron emission tomography (PET) scans. PET scans
make detailed, computerized pictures of areas inside the body where the drug is used. Giving
panitumumab-IRDye800 and 89Zr-panitumumab to patients with head and neck cancer may help
doctors find metastatic lymph nodes better than current methods [positron emission tomography
(PET); computed tomography (CT); magnetic imaging resonance (MRI), or combinations].
Official Title
Pilot Study Evaluating Panitumumab-IRDye800 and 89Zr-Panitumumab for Dual-Modality Imaging for Nodal Staging in Head and Neck Cancer
Stanford Investigator(s)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Eligibility
Inclusion Criteria:
- Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.
- Subjects diagnosed with any T stage, any subsite within the head and neck that are
scheduled to undergo surgical resection. Subjects with recurrent disease or a new
primary will be allowed.
- Planned standard of care surgery with curative intent for squamous cell carcinoma.
- Hemoglobin ≥ 9 gm/dL.
- White blood cell count > 3000/mm³.
- Platelet count ≥ 100,000/mm³.
- Serum creatinine ≤ 1.5 times upper reference range.
Exclusion Criteria:
- Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive
heart failure (CHF); significant liver disease; or unstable angina within 6 months
prior to enrollment.
- Previous bilateral neck dissection.
- History of infusion reactions to monoclonal antibody therapies.
- Pregnant or breastfeeding.
- Magnesium or potassium lower than the normal institutional values.
- Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide,
amiodarone, sotalol) antiarrhythmic agents.
- Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
- Severe renal disease or anuria.
- Known hypersensitivity to deferoxamine or any of its components.
Intervention(s):
drug: Panitumumab-IRDye800
device: Explorer Air camera
device: PDE-NEO II camera
device: FIS-00 fluorescence imaging system (FIS)
device: Da Vinci Firefly Imaging System
device: IGP-ELVIS-v4 Macroscopic Specimen Imager
device: Vevo 3100 LAZR-X
device: Pearl Triology Imaging System
device: Odyssey CLx Imaging System
device: Leica fluorescence microscope
drug: 89-Zirconium (Zr-89) Panitumumab
device: Pinpoint IR IR9000 fluorescence imaging system (FIS)
device: SPY-PHI IR9000 fluorescence imaging system (FIS)
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Alexander Ayon Valencia
650-498-5185